Provided by Tiger Fintech (Singapore) Pte. Ltd.

ASCLETIS-B

13.580
+1.68014.12%
Volume:9.95M
Turnover:129.77M
Market Cap:13.47B
PE:-41.28
High:13.680
Open:11.920
Low:11.890
Close:11.900
52wk High:18.750
52wk Low:1.480
Shares:992.00M
HK Float Shares:992.00M
Volume Ratio:3.56
T/O Rate:1.00%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.329
ROE:-12.77%
ROA:-12.32%
PB:6.59
PE(LYR):-41.28
PS:5204.59

Loading ...

Ascletis Pharma Repurchases 100,000 Shares for HKD 926,520 in HKEX Disclosure Return

Reuters
·
Oct 22

ASCLETIS-B (01672) Spends Approximately HKD 926,500 to Repurchase 100,000 Shares on October 22

Stock News
·
Oct 22

Ascletis Pharma Inc. (01672) Announces Share Repurchase and Treasury Share Update

Bulletin Express
·
Oct 22

Hong Kong Stock Buyback Statistics | October 20

Stock News
·
Oct 20

Ascletis Pharma Inc. (1672) Announces Completion of Enrollment in U.S. Phase IIa Study for Once-Monthly Subcutaneous Depot Formulation ASC30

Bulletin Express
·
Oct 20

ASCLETIS-B (01672) Completes the Enrollment of Asc30, a Monthly Subcutaneous Depot Formulation for Obesity in Phase IIa Study in the U.S.

Stock News
·
Oct 20

Ascletis Completes Enrollment in US Phase IIa Trial of Once-Monthly GLP-1R Agonist ASC30 for Obesity

Reuters
·
Oct 20

Ascletis Pharma Inc. (01672) Reports Share Repurchases and Updated Issued Shares

Bulletin Express
·
Oct 17

Ascletis Pharma Inc filed next day disclosure return to HKEX announcing repurchase of 100000 shares at HKD 915250

Reuters
·
Oct 17

ASCLETIS-B (01672) Spends HKD 915,250 to Repurchase 100,000 Shares on October 17

Stock News
·
Oct 17

Ascletis Pharma Inc files next day disclosure return to HKEX announcing repurchase of 100000 shares for HKD 948700

Reuters
·
Oct 15

ASCLETIS-B (01672) Invests HKD 948,700 to Buy Back 100,000 Shares on October 15

Stock News
·
Oct 15

Hong Kong Stock Market Preview | International Gold Prices Reach New Historic High, Powell Signals Potential End to Balance Sheet Reduction

Stock News
·
Oct 15

Ascletis Pharma Inc - Denifanstat Shows Favorable Safety With Mild or Moderate Treatment-Emergent Adverse Events

THOMSON REUTERS
·
Oct 14

Ascletis Pharma Inc - Denifanstat Meets All Efficacy Endpoints in Phase Iii Trial

THOMSON REUTERS
·
Oct 14

ASCLETIS-B (01672) Completes Pre-NDA Communication with NMPA for Denifanstat (ASC40) New Drug Application

Stock News
·
Oct 14

Ascletis Pharma Announces Positive Phase III Results for Denifanstat (ASC40) in Moderate-to-Severe Acne and Completes Pre-NDA Consultation with China NMPA

Reuters
·
Oct 14

Hong Kong Stocks Movement | Pharmaceutical Stocks Continue Multi-Day Decline Amid Short-Term External Environment Changes, Institutions Remain Optimistic About Long-Term Industry Development Trends

Stock News
·
Oct 14

ASCLETIS-B (01672) Repurchased 100,000 Shares for Approximately HK$968,300 on October 13

Stock News
·
Oct 13

Ascletis Pharma Hones In on Weight-loss Drug for Further U.S. Studies

MT Newswires Live
·
Oct 13